Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market dominated by heavyweights…
Danish biotech Zealand Pharma is targeting the"next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly.
However, Steensberg said it's the company's separate obesity drug candidate, Petrelintide, a long-acting amylin analog, which could set it apart from the competition, offering an alternative for users who cannot tolerate GLP-1s.Salesforce's UK chief urges government not to regulate all AI companies in the same way
"It's two very different human experiences," Steensberg said, comparing GLP-1s with amylin analogs."If you work on satiety, it will be a more pleasant experience. So once you get into it, you can stay long-term treatment." "If we can develop a molecule that is giving patients the weight loss they're looking for with a very benign tolerability profile, and we can also show risk reduction when it comes to cardiovascular health, I think we have all the reasons to believe it could become a first-line therapy," Steensberg told CNBC in the interview Thursday.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo and Eli contender Zealand Pharma heralds its obesity drug alternative: It's our ‘crown jewel'Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market dominated by heavyweights…
Read more »
Wegovy and Zepbound rival targeting ‘next generation' of obesity drugs, Zealand Pharma CEO saysDanish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market dominated by heavyweights…
Read more »
Morgan Stanley says this pharma stock can rally more than 60% thanks to its narcolepsy treatmentThis stock could be at the forefront of a leading narcolepsy treatment that can send its shares soaring, according to Morgan Stanley.
Read more »
Lilly Collins Expertly Layers a Studded Sheer Top Over Her Cargo ShortsSay “bonjour” to Darren Star’s latest creation. The “SATC” and “Younger” creator returns to the small screen with Netflix’s “Emily in Paris,” starring Lily Collins.
Read more »
Why Eli Lilly and Palo Alto Networks are both up on news from their competitorsEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Read more »
FTC Sues Big Pharma Middlemen for Inflating Insulin PricesJessica Corbett is a senior editor and staff writer for Common Dreams.
Read more »